Fresenius : Conference Call Preliminary Q2/2022 Results

Conference Call │ Q2/22 Preliminary Results

Bad Homburg, 28 July 2022

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings the availability of financing, and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Q2/22 Preliminary Results, 28 July 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

2

Key messages

Weak Q2 amid intensifying	FY/22 Group guidance driven	Medium-term targets: Sales	"Meet the Management" with
U.S. labor shortages and	by Fresenius Medical Care's	CAGR specified; net income1	Fresenius Kabi on October 7,
accelerating macro-economic	outlook adjustment	CAGR no longer believed to	2022
challenges		be achievable

Marked by increased	In line with expectations;	Solid organic growth in	Supply chain disruptions and
headwinds from U.S. labor	biosimilars business	Germany and Spain based on	higher material costs remain
market and global inflation	progressing well	healthy activity levels	headwinds

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

Q2/22 Preliminary Results, 28 July 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

3

Fresenius Group: Temporary headwinds driven by geopolitical turmoil and the COVID-19 pandemic weighing on FY/22 earnings growth

Headwinds for net income development FY/22e Reconciliation to new guidance

		Low	Low-to-mid
single-digit	single-digit
net income	net income
	growth		decline

Material

costs Energy costs

Missing

growth Labor costs

Material, supply chain and energy costs

• Meaningful increases across all segments

Missing growth

• Staff shortages limit growth e.g. onboarding opportunities for new patients in dialysis clinics

Labor costs

• Headwinds primarily at FMC in the U.S. patient-facing service business

Offset

• Including monies from the U.S. government's Provider Relief Fund
• Compensating measures include tight cost control and product price increases wherever possible

Expectations H2/2022

• Neither meaningful worsening of macro challenges nor major COVID- 19 pandemic effects leading to lock-downs factored in

• Overall, we consider headwinds as temporary and not structural

Q2/22 Preliminary Results, 28 July 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

4

Kabi: Solid Q2/22 on tough comps

					• Market shares remain robust in key NAM and
		YoY		YoY	China markets
€m	Q2/22	cc	H1/22	cc	− NAM: Price pressure easing to low single-
						digits in our base product portfolio
Sales	1,896	2%1	3,743	1%1
	− China: Marked by significant NVBP tender
EBIT	271	-15%2	564	-8%2
	related price pressure ahead of Q3/Q4
						annualization
					• FDA inspected Melrose Park facility - feedback
						expected in Q3/22
					• Biosimilar business progressing well
					• Ivenix acquisition closed during Q2;
						large volume pump receiving promising
						customer feedback
					•	mAbxience closing imminent

All figures preliminary figures

Before special items

1. Organic
2. Excluding Ivenix acquisition

Q2/22 Preliminary Results, 28 July 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

5